Mounjaro® and rash

Three kinds of skin reaction

• Injection-site reactions: redness, itching or swelling where you injected. Reported by 3.2% on Mounjaro® against 0.4% on placebo in the US diabetes trials, mostly mild ^[1][3]. They are covered in detail on the Mounjaro® injection-site reactions page.
• Hypersensitivity reactions: the labels’ term for allergic-type reactions anywhere on the body, with hives (urticaria), eczema, rash and dermatitis as examples, sometimes severe ^[1][3].
• Serious allergic reactions: anaphylaxis and angioedema, deep swelling of the face, lips, tongue or throat, reported after approval. Europe rates them rare ^[1][3].

How often allergic-type reactions were reported

The US label gives one placebo-controlled figure for adults with type 2 diabetes. Europe, where tirzepatide is also authorised for weight management, reports four trial programmes, including studies in sleep apnoea and in heart failure ^[1][3]. In every programme the placebo group also reported such reactions, which shows how often rashes and itching occur in any large group of people over months.

Antibodies and timing

About half of adults on Mounjaro® in seven diabetes trials developed antibodies to tirzepatide ^[1]. Those who did reported allergic-type reactions slightly more often, 4.1% against 3.0% without antibodies ^[1]. A pooled analysis of the same trials found that most of these reactions were neither serious nor severe and that most occurred or cleared regardless of antibody status, and the antibodies did not change how well tirzepatide worked ^[5]. Antibody testing is not part of routine care, so this is background rather than something to act on.

In Canada’s paediatric trial, the two allergic reactions in children with antibodies were hives and bronchospasm, a tightening of the airways ^[4]. The labels do not say how soon after starting or after a dose increase skin reactions appear. One published case describes a 25-year-old woman who had no problems on lower doses but developed widespread hives and lip swelling over four days after her first 10 mg dose; skin testing confirmed a tirzepatide allergy and she later tolerated semaglutide under supervision ^[8]. A single case shows what can happen, not how often.

Ingredients that differ between pens

Not every Mounjaro® presentation has the same inactive ingredients. The single-dose pen and single-dose vial contain tirzepatide with sodium chloride, sodium phosphate and water. The multi-dose KwikPen and multi-dose vial add benzyl alcohol, glycerin and phenol as well ^[1][2]. The European leaflet for the KwikPen states that benzyl alcohol may cause allergic reactions ^[3], and Canada’s patient information names benzyl alcohol among the ingredients that people allergic to it should avoid ^[4].

Mounjaro® must not be used by anyone who has had a serious allergic reaction to tirzepatide or to any of its ingredients ^[1]. If you have reacted to a preservative before, tell your prescriber and pharmacist which presentation you use. The labels also ask for caution in people who have had anaphylaxis or angioedema with another GLP-1 medicine, because it is unknown whether they are more likely to react to tirzepatide ^[1][4].

What studies beyond the label show

A 2026 meta-analysis of randomised GLP-1 trials found injection-site reactions about three and a half times more common than with comparators, while general skin reactions were infrequent and not significantly raised ^[6]. A review that also searched the US FDA report database found that skin and injection-site problems made up about a third of tirzepatide reports, similar to dulaglutide and more than semaglutide; most were mild to moderate ^[7].

Report databases depend on who chooses to report and cannot show how often a reaction occurs or prove that the medicine caused it ^[7]. The trial figures in the table above remain the better guide to frequency.

Rashes with other causes

MedlinePlus lists many common causes of rash: contact dermatitis from soaps, cosmetics, latex or clothing dyes, eczema in people with allergies or asthma, psoriasis, shingles, infections, insect bites and other medicines ^[9]. Hives are most often an allergic reaction to a food or drug, but infections and stress can also cause them ^[10].

People with type 2 diabetes often take other medicines too. MedlinePlus lists rash among possible side effects of metformin ^[12]. A new antibiotic, painkiller or skin product started in the same week is worth mentioning, because the timing alone cannot tell you which one is responsible.

Gentle care for a mild rash

The Mounjaro® documents give no home-care advice for rashes; they ask you to stop and seek help for signs of a serious reaction ^[2]. For a mild rash without those signs, MedlinePlus describes general steps, and it adds that you should contact your provider when you have started a new medicine.

• Wash with warm, not hot, water and a gentle cleanser; pat dry rather than rubbing ^[9].
• Stop any new cosmetics or lotions and avoid putting lotions directly on the rash ^[9].
• Leave the area uncovered when you can ^[9].
• Over-the-counter 1% hydrocortisone cream may soothe many rashes, and oral antihistamines may ease itching; ask a pharmacist which suits you ^[9].
• Do not stop or change a prescribed medicine without talking to your provider ^[9].

Mounjaro® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.